Acne keloidalis nuchae (AKN) is one of the chronic forms of scarring folliculitis, affecting
predominantly the occipital scalp, seen mostly in men of African descent. Duobrii has the
advantage of being the only high potency topical steroid-retinoid combination approved by the
FDA with dermatologic indication. Researchers are proposing the off-labeled use of Duobrii
for the management of early-mild AKN. The research team hypothesizes that subjects will
experience significant clinical improvement in lesion counts. Patients will be followed with
visits scheduled at baseline, 4 weeks, 8 weeks, and 12 weeks. During these in-clinic visits,
there will be surveys regarding the severity of AKN symptoms, photographs, and clinical
assessments.